Kynam Capital Management, LP - Significant Ownership

Signature - Title
Jared Keller - COO
Location
Princeton, NJ
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Kynam Capital Management, LP.

Significant Ownership of Kynam Capital Management, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SNDX Syndax Pharmaceuticals Inc Common Stock, par value $0.0001 per share 9.98% $107M 8.52M Kynam Capital Management, LP Dec 31, 2024
ENGN enGene Holdings Inc. Common Shares, no par value per share 9.8% $26.4M 4.99M Kynam Capital Management, LP Dec 31, 2024
CLDX Celldex Therapeutics, Inc. Common Stock, par value $0.001 7.63% $107M 5.06M Kynam Capital Management, LP Dec 31, 2024
DVAX DYNAVAX TECHNOLOGIES CORP Common Stock, par value $0.001 per share 4.99% $90.5M 6.56M Kynam Capital Management, LP Dec 31, 2024
TSVT 2seventy Bio, Inc. Common Stock, par value $0.0001 per share 0% $0 0 Kynam Capital Management, LP Mar 11, 2025

Schedules 13D/G Reported by Kynam Capital Management, LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.